Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study
Authors' conclusion
Initiation of GLP1RAs was not associated with increased risk of mental health disorders compared with DPP4 inhibitors. Differences in the risk of depression and anxiety were observed compared with SGLT2 inhibitors.
Study context
- Population
- Patients aged ≥18 years initiating GLP1RAs, SGLT2i or DPP-4i for T2D, Korean claims database 2012–2022propensity score matched
- Participants
- 18,825 / 623,750 / 5,762 / 874,902
- Exposure
- GLP-1 RA vs DPP-4i and vs SGLT2i
- GLP1RAn = 18,825
- SGLT2 inhibitorsn = 623,750reference
- GLP1RAn = 5,762
- DPP4 inhibitorsn = 874,902reference
- Outcome
- Depression, anxiety, sleep disorders and suicide
Methodological detailspropensity score matching, Cox proportional hazards models, Korean claims database 2012–2022
- Propensity score matching
- Cox proportional hazards models
- Korean claims database 2012–2022
Main finding
As reported in the abstract
Mental health disorders
Estimate (95% CI)
GLP1RA (vs DPP4i)vs DPP4 inhibitors
HR (depression) 1.00(0.83–1.20)
GLP1RA (vs DPP4i)vs DPP4 inhibitors
HR (anxiety) 0.92(0.77–1.08)
GLP1RA (vs DPP4i)vs DPP4 inhibitors
HR (sleep disorder) 1.14(0.97–1.33)
GLP1RA (vs SGLT2i)vs SGLT2 inhibitors
HR (depression) 1.20(1.09–1.31)
GLP1RA (vs SGLT2i)vs SGLT2 inhibitors
HR (anxiety) 1.09(1.00–1.19)
Observational data: associations, not effects.
Original publication
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study. Diabetes Obes Metab. Published 30 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →